Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer

Lung

Volumn 184, Issue 3, 2006, Pages 133-139

  Kataoka, Kensuke ^a   Suzuki, Ryujiro ^b   Taniguchi, Hiroyuki ^c   Noda, Yasunobu ^b   Shindoh, Joe ^d   Matsumoto, Syuichi ^e   Watanabe, Yoshiaki ^f   Honda, Kousuke ^g   Suzuki, Kiyoshi ^h   Baba, Kenji ⁱ   Imaizumi, Kazuyoshi ^a   Kume, Hiroaki ^a   Hasegawa, Yoshinori ^a   Takagi, Kenzo ^j  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c TOSEI GENERAL HOSPITAL   (Japan)

^d OGAKI MUNICIPAL HOSPITAL   (Japan)

^e Komaki Municipal Hospital   (Japan)

^f Kamo Hospital   (Japan)

^g Kakegawa City General Hospital   (Japan)

^h Meijo Hospital   (Japan)

ⁱ AICHI MEDICAL UNIVERSITY   (Japan)

^j NAGOYA UNIVERSITY   (Japan)

more..

Author keywords

Carboplatin; Docetaxel; Non small cell lung cancer; Phase I II; Stage IV

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TAXOIDS;

EID: 33747146195     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-005-2572-1     Document Type: Article

References (19)

1. Alexopoulos K, Kouroussis C, Androulakis N, et al. (1999) Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 43:257-262
2. Belani CP, Eizig A, Bonomi P, et al. (2000) Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 11:673-678
3. Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20:23S-33S
4. Calvert AH, Newell DR, Gumbrell LA, et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
5. Fossella FV, DeVore R, Kerr RN, et al. (2000) Randomised phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362
6. Fossella F, Pereira JR, von Pawel J, et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 21:3016-3024
7. Francis PA, Rigas JR, Kris MG, et al. (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237
8. Fry WA, Menck HR, Winchester DP (1996) The National Cancer Data Base report on lung cancer. Cancer 77:1947-1955
9. Gelmon KA (1998) The fine points of end points: phase II trials in lung cancer. Ann Oncol 9:1045-1046
10. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422
11. Gralla RJ, Osoba D, Kris MG, et al. (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
12. Huisman C, Smit EF, Giaccone G, Postmus PF (2000) Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18:3722-3730
13. Kasahara K, Myo S, Iwasa K, et al. (2002) A phase I study of carboplatin and docetaxel for advanced non-small-cell lung cancer using the continual reassessment method. Jpn J Clin Oncol 32:512-516
14. Kunitoh H, Watanabe K, Onoshi T, et al. (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14:890-892
15. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-smallcell lung cancer. Results of a meta-analysis of the literature. Chest 106:861-865
16. Mertens WC, Higby DJ, Brown D, et al. (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373-1378
17. Non-small-Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
18. Shepherd FA, Dancey J, Ramlau R, et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103
19. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, et al. (2001) A Phase II study of docetaxel and carboplatin in the treatment of non-small-cell lung cancer. Lung Cancer 32:281-287